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Biomarkers of infection, namely C-reactive protein and procalcitonin (PCT), are potentially useful in the diagnosis of
infection as well as in the assessment of its response to antibiotic therapy. C-reactive protein variations overtime
appears to have a good performance for the diagnosis of infection. Procalcitonin shows a better correlation with
clinical severity. In addition, to overcome the worldwide problem of antibiotic overuse as well as misuse, biomarker
guidance of antibiotic stewardship represents a promising new approach. In several randomized, controlled trials,
including adult critically ill patients, PCT guidance was repeatedly associated with a decrease in the duration of
antibiotic therapy. However, these trials present several limitations, namely high rate of patients’ exclusion, high rate
of algorithm overruling, long duration of antibiotic therapy in the control group, disregard the effect of renal failure
on PCT level, and above all a possible higher mortality and higher late organ failure in the PCT arm. In addition,
some infections (e.g., endocarditis) as well as frequent nosocomial bacteria (e.g., Pseudomonas aeruginosa) are not
suitable to be assessed by PCT algorithms. Therefore, the true value of PCT-guided algorithm of antibiotic
stewardship in assisting the clinical decision-making process at the bedside remains uncertain. Future studies
should take into account the issues identified in the present review.
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Introduction
During the past three decades, the incidence of sepsis has
been consistently rising, surpassing that of cardiac failure
and has an annual mortality rate above acute myocardial
infarction [1,2]. A recent report from the Healthcare Cost
and Utilization Project found that hospital costs increased
almost 25 % (inflation-adjusted) from 2001 to 2007 [3].
Among the top ten conditions with the most rapidly in-
creasing hospital costs, three were infections, with “blood
infection (septicemia)” showing the largest growth in cu-
mulative costs (174.1 %) and the highest aggregate costs
(12.3 billion USD in 2007).
Consequently sepsis is a major public health issue that
can affect all population, including healthy people, al-
though there is a predominance in elderly patients with* Correspondence: povoap@netcabo.pt
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reproduction in any medium, provided the origmultiple or severe comorbidities. However, during the
past 15 years, several reports showed a sustained and
continuous improvement in mortality of severe sepsis
and septic shock, although it remains exceedingly high,
ranging between 30-50 % [4-6]. Yet, this improvement in
outcome cannot be attributed to the introduction of a
new drug or treatment but to an improvement of the
process-of-care with more rapid diagnosis and treatment
[6,7]. Even though a delay in the institution of antibiotic
therapy is markedly associated with a worse prognosis,
antibiotic overuse should be avoided and interventions
to reduce the duration of antibiotic therapy were asso-
ciated with lower mortality and length of stay as well as
a decrease in the prevalence of multidrug-resistant
microorganisms [8,9].
With the goal of shortening the duration of antibiotic
therapy, the efficacy of procalcitonin (PCT)-guided anti-
biotic stewardship algorithms have been tested in differ-
ent clinical settings [10]. As a result, the discussion of
the available strategies to decrease the duration of anti-
biotic therapy, with and without biomarkers, in particu-
lar in the critical care setting, seems timely and relevant.is is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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severe sepsis?
The diagnosis of infection is not straightforward, be-
cause there is no “gold standard” test [11]. Consequently,
antibiotics are frequently prescribed without a definite
diagnosis, because a delay in treatment is associated with
decreased survival [12]. Even more difficult than diagno-
sis, is monitoring of infection response to antibiotics
[13]. Currently, the assessment of response relies on the
resolution of the same criteria used in the diagnosis. Be-
cause the inflammatory cascade plays a central role in
host-pathogen interaction and in infection control
mechanisms, these mediators have been assessed as sur-
rogate markers of infection, both in diagnosis and in
monitoring response [11]. Unfortunately the “ideal” bio-
marker has not yet been discovered (Table 1).Do we need biomarkers to guide/reduce antibiotic
therapy in severe sepsis, namely in VAP?
Two landmark studies were published that evaluated the
impact of shorter duration of antibiotic therapy in
ventilator-associated pneumonia (VAP) [15,16]. The
PneumA trial [15] was a prospective, randomized, con-
trolled trial (RCT) in 51 French intensive care units
(ICU) designed to assess whether 8 days was as effective
as 15 days of adequate antibiotic therapy in microbio-
logically documented late-onset VAP (N = 402). The
authors showed that an 8-day course of antibiotics was
as effective as a 15-day treatment (all-cause mortality:
18.8 % vs. 17.2 %).
The second study was a single-center, prospective
RCT designed to evaluate the effectiveness and safety of
a discontinuation policy on the duration of antibiotic
therapy of VAP (N = 290) [16]. The authors showed thatTable 1 Characteristics of the ideal biomarker of infection
[13,14]




5 Good sensitivity and good specificity
6 Dynamic – rapid increases and decreases
7 Level not dependent of the underlying pathology and not
modified by any treatment or intervention unless interventions
related to the source control and/or antibiotic therapy
8 Continuous and not a discrete variable
9 Correlation with clinical severity and mortality
10 Prolonged and successive infections without “exhaustion” or “fatigue”
11 Inexpensive
12 Easily availablean active discontinuation policy could safely decrease
the duration of antibiotic therapy to 6 days (p = 0.001).
Both groups presented similar hospital mortality and
ICU and hospital length of stay (LOS) (p = 0.357,
p = 0.798, p = 0.865, respectively). These findings sug-
gest that shorter courses of antibiotic therapy, 6–8 days, in
VAP can be safely achieved without the use of biomarkers.C-reactive protein and procalcitonin biology
Among all biomarkers of infection those more fre-
quently studied are C-reactive protein (CRP) and PCT
[11]. Before using these biomarkers in clinical practice, it
is essential to know its biology, strengths, and
limitations.
Plasma CRP, like all other acute phase proteins, is ex-
clusively synthesized in the liver in response to interleu-
kin 6 [17,18]. Four to 6 hours after an inflammatory
insult, CRP secretion begins. Its concentration doubles
every 8 hours and peaks at 36–50 hours [19-21]. With
the elimination or removal of the primary inflammatory
stimulus, CRP falls rapidly with a first-order kinetics pat-
tern of elimination with a half-life of 19 hours [22]. C-
reactive protein concentration rises whenever an inflam-
matory process is present and its serum concentration
depends only on the intensity of the stimulus and on the
rate of synthesis [19,21,22]. C-reactive protein level is in-
dependent of the underlying disease and is not modified
by any therapy or intervention such as renal replacement
therapy (RRT) [23], systemic steroids [24], or neutro-
penia [25].
The pathophysiological role of PCT in sepsis is not
fully understood [10]. After an inflammatory stimulus,
PCT is detectable as soon as 3-4 hours, peaking at 14-
24 hours [26-29]. After removal of the inflammatory
stimulus, PCT half-life ranged from 22-35 hours [29].
There are several well-recognized limitations to the use
of PCT as a surrogate marker of infection. It has been
shown that in septic cancer patients with leukopenia
PCT concentrations were lower [30]. Besides renal func-
tion is a major determinant of PCT levels [10,31,32], and
in addition, PCT is markedly cleared by different techni-
ques of RRT [23,33].Assays to measure C-reactive protein and procalcitonin
The characteristics of the assays used to measure
the marker are a fundamental aspect when dealing with
biomarkers [34]. The available immunoassays of CRP
measurement are reliable, stable, and highly reproducible
[35]. Besides they are inexpensive (approximately 4€ in
Europe), rapid (15–30 minutes), and with a limit of de-
tection of 0.3-5 mg/L [36]. This limit of detection of
CRP is acceptable to its utilization as a biomarker in
diagnosis and in monitoring response to antibiotics [21].
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a high sensitivity [10]. Only the immunoassay, based on
a time-resolved amplified cryptate emission (TRACE)
technology (Kryptor PCT assay, Brahms), has a reason-
able limit of detection: 0.06 ng/mL [37]. The assay time
is rapid (19 min) but still quite expensive (25-30€ in
Europe) [10]. All the other less sensitive assays, namely
the semiquantitative immunochromatographic method
(PCT-Q, Brahms) and the luminescence immunoassay
(PCT LIA, Brahms), should be used with caution and
never for antibiotic stewardship [10,38,39].What is the PCT algorithm for stewardship of
antibiotic therapy?
The proposed algorithms on antibiotic stewardship are
based on different PCT cutoff ranges. These cutoffs were
derived from several well-conducted, prospective, observa-
tional studies and were validated in different RCT [40]. The
PCT algorithm for primary care and emergency depart-
ments can be summarized as follows: antibiotics were more
or less discouraged (<0.1 ng/mL or 0.1–0.25 ng/mL) or
encouraged (>0.25–0.5 ng/mL or >0.5 ng/mL) [10].
According to these PCT cutoff ranges, bacterial etiology
was considered very unlikely, unlikely, likely, and very likely,
respectively [10]. To prevent not treating an infection, some
overruling criteria were included in the algorithm (Figure 1)
[10].
For patients in the ICU, the algorithm for antibiotic
stewardship was similar but with somewhat higher PCT
cutoff ranges [40]. Likewise, if antibiotics were withheld
the algorithm recommends a clinical reevaluation and
subsequent PCT measurement after 6-24 hours. In theFigure 1 Procalcitonin algorithm for stewardship of antibiotic therapycase of antibiotic therapy, PCT should be monitored
daily. Antibiotics should be discontinued when PCT
decreases >80 % of the initial level or if an absolute
PCT value <0.5 ng/mL is reached. Again, if PCT
levels remain elevated, treatment failure, potential
infectious complications or superinfection should be
considered [40].
Studies of PCT-guided algorithms of antibiotic
stewardship in adult critically ill patients
Characteristics of selected RCT
A total of 7 RCT dealing with PCT-guided antibiotic
stewardship in adult critically ill patients were identified
for further discussion [41-47]. They were published be-
tween 2007 and 2011 (Table 2). A total of 2,190 adult
critically ill patients were included in the above-
mentioned RCTs (Table 2). From the included patients,
1,331 (60.8 %) presented nosocomial infections and the
remaining 859 were community-acquired. Pneumonia
was the most frequent infection in four studies,
whereas peritonitis was more frequent in the other
three (n = 33 [43], n = 19 [44], and n = 59 [46]).
Reasons for exclusion of screened patients from the studies
The clinical impact of an intervention is somehow
dependent on its applicability. In the seven selected
RCT, the rate of exclusion ranges from 0.3 % [47] to
84 % [43]. However, with the exception of the larger
RCT that presented the lower exclusion rate [47], in all
the others the rates of exclusion were exceedingly high,
84 % [43], 72 % [41], 78 % [44], 38 % [45], 72 % [46],
and 52 % [42].; adapted from [10].













Svoboda, 2007 [43] 72 381 (84) 0/72 NA PCT-Q
Nobre, 2008 [41] ProSEP 79 203 (72) 53/26 52 TRACE
Schroeder, 2009 [44] 27 98 (78) 0/27 8 PCT LIA yes
Stolz, 2009 [45] ProVAP 101 63 (38) 0/101 101 TRACE yes
Hochreiter, 2009 [46] ProSICU 110 285 (72) 0/110 43 PCT LIA
Bouadma, 2010 [42] PRORATA 601 685 (52) 326/275 394 TRACE yes 4 (1.7 %)/15 (4.8 %)



















Table 2 Principal characteristics of the randomized controlled trials assessing the role of PCT-guided antibiotic stewardship in adult critically ill patients
(Continued)




















16.1 ± 6.9/19.4 ± 8.9 10/38 (26 %)/13/34 (38 %)




8/39 (20.5 %)/8/40 (20 %)
6.6 ± 1.1/8.3 ± 0.7 16.4 ± 8.3/16.7 ± 5.6 3/14 (21.4 %)/3/13 (23.1 %)
10 (6–16)/15 (10–23) 16 13 (7–21)/13.5 (8–22.2) 7/51 (13.7 %)
/6/50 (12 %)
8/51 (16 %)/12/50 (24 %)
5.9 ± 1.7/7.9 ± 0.5 15.5 ± 12.5/17.7 ± 10.1 15/57 (26.3 %)/14/53 (26.4 %)




65/307 (21.2 %)/64/314 (20.4 %) 92/307 (30 %)/
82/314 (26.1 %)
6 (3–11)/4 (3–10) 17.9 6 (3–12)/5 (3–11) 190/604 (31.5 %)/191/596 (32 %) 231/604 (38.2 %)/
220/596 (36.9 %)
Results are expressed as mean ± standard deviation or median (interquartile range) unless otherwise indicated.
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sion. In three studies the description was very poor
[43,44,46]. In the other RCT, it is clear that common
ICU infections are excluded [41,42,45], namely caused
by Pseudomonas aeruginosa, Acinetobacter baumannii,
as well as frequent clinical situations, namely endocardi-
tis or infections that require long-course antibiotics and
immunosuppressed patients.
PCT measurement methodology
The quality of the studies also is largely dependent of
the methodology used to measure PCT plasma concen-
trations. One RCT used a semiquantitative immuno-
chromatographic method [43], and two the less sensitive
luminescence immunoassay [44,46], which are currently
not recommended for antibiotic stewardship [10]. The
ultrasensitive methodology was used in the remaining
four trials [41,42,45,47].
PCT-guided algorithms of antibiotic stewardship
Each of the RCT describes a specific PCT-guided algo-
rithm of antibiotic stewardship; however, as a whole, the
main frame was quite similar to that previously
described. In four RCT, the algorithm was designed to
assist in the decision to stop antibiotics [41,44-46], in
two to assist in the decision to start and to stop antibio-
tics [42,43], and finally to start or escalate antibiotics
[47]. In two studies, the PCT guidance also impacted the
management of patients because concomitant interven-
tions were performed [43,47].
The standard of care
In the seven RCT, the control group was managed
according to the standard of care. This is vague, because
there is substantial difference between usual care, the
standard of care, and the best care [48]. According to
the above-mentioned VAP studies, the course of antibio-
tics could be safely reduced to 6–8 days [8,15,16].
Therefore, it would be important to know whether
patients in the control group have a minimum duration
of antibiotic therapy. This was the case in three RCT
[42,44,45]. In one study, the antibiotic duration was cal-
culated according to the underlying infectious pathology
[44]. In other trial, dealing only with VAP, the minimum
duration of antibiotic therapy in the control group was
15 days [45]. Finally, in the last trial, the recommenda-
tions were for community-acquired pneumonia 7–10
days with a longer duration, 14 days, if pneumonia was
caused by Legionella pneumophila, Mycoplasma pneu-
moniae, or Chlamydia pneumoniae, and for VAP 8–15
days [42].
This raises two issues. First, several years after the
publication of RCTs showing that 6–8 days of anti-
biotic therapy in VAP is safe [15,16], it may not beacceptable to have control groups treated for so long.
Second, the attending physician was not allowed to
use the clinical and laboratory course of the patient as
a stopping rule.
Impact of PCT-guided algorithm in the decision to
start antibiotics
In two trials, the PCT-guided algorithm was designed to
assist in the decision to start antibiotics [42,43]. In one
study, all patients received antibiotics at inclusion; how-
ever, the criteria to start were not very clear and
in addition the use semiquantitative method of PCT
measurement precluded further comment [43]. In the
PRORATA trial at inclusion, paradoxically more patients
(N = 15) in the control group did not receive antibiotics,
because the attending physician considered the patient
not infected, than in the PCT-guided group (N = 4) [42].
Impact of PCT-guided algorithm in the decision to
stop antibiotics
In five RCT, the PCT-guided algorithm was designed to
assist in the decision to stop antibiotics [41,42,44-46].
All were able to decrease the duration of antibiotic ther-
apy in ICU patients as well as the antibiotic-free days,
28 days after inclusion.
The duration, in days, of antibiotic therapy of the first
episode of infection was shorter in the PCT-guided arm
in all studies, 6 (3–34) vs. 9.5 (2–33) (p = 0.15) [41],
6.6 ± 1.1 vs. 8.3 ± 0.7 (p < 0.001) [44], 3 (0–8) vs. 5 (1–9.5)
(p = not shown) [45], 5.9 ± 1.7 vs. 7.9 ± 0.5 (p < 0.001)
[46] and 6.1 ± 6.0 vs. 9.9 ± 7.1 (p < 0.0001) [42]. Similarly,
the total duration, in days, of antibiotic therapy was shorter
in the PCT-guided group.
Consequently, the exposure to antibiotics, expressed
by the antibiotic-free days, was lower in patients from
the PCT arm [41,42,45].
Impact of PCT-guided algorithm in the decision to start
and/or escalate antibiotics
Recently, the largest, multicenter trial to assess a PCT-
guided algorithm was published: the PASS trial [47]. Its
design was based on the finding of the so-called “alert
PCT” [49]. It consists of PCT > 1.0 ng/mL or not de-
creasing <10 %/d to indentify infected patients at risk of
complications or treatment failure. In this observational
study, the presence of an “alert PCT” was significantly
associated with 90-day all-cause mortality [49]. The
interventions in the “alert PCT” days consisted on cul-
tures, radiology, and empiric antibiotic therapy (pre-
scription or broaden spectrum antibiotic according to an
algorithm) with the goal to reduce mortality.
The use of large-spectrum antibiotics was substantially
increased in the PCT arm with a shorter time to start
(p < 0.0001) and a longer exposure (p < 0.001) [47].
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was similar between groups with the exception of blood-
stream infections, shorter in the PCT-guided group [47].
Total duration of antibiotic therapy was longer in the
PCT-guided arm: (median) 6 [range, 3-11] vs. 4 days
[range, 3-10] (p < 0.05).Compliance with PCT-guided algorithm
In addition to the extent of excluded patients, the degree
of algorithm overruling is an indirect measure of its clin-
ical applicability as well as of its true impact in the clin-
ical decision making process. In the PRORATA trial
[42], at inclusion 89 patients had a PCT <0.5 μg/L and
according to the algorithm antibiotics were “discour-
aged” or “strongly discouraged.” However, in 73 % of
patients (n = 65) the attending physician overruled this
recommendation, because they considered the patient
“infected” despite a low PCT level. This represents a
21 % of algorithm overruling at inclusion (65/307).
In three RCT that assessed the impact of PCT-guided
algorithm in the decision to stop antibiotics, it was pos-
sible to assess the rate of overruling [41,42,45]. In two
studies, the rate of overruling of stopping rules were
19 % (6/31) [41] and 16 % (8/51) [45]. In both cases, the
attending physician prolonged antibiotic therapy despite
a low PCT level. In the PRORATA trial [42], the reasons
for overruling were: n = 39 patients, antibiotics were
stopped despite a PCT > 0.5 μg/L, because infection
was considered clinically cured; n = 79 patients, anti-
biotic therapy was prolonged despite a PCT < 0.5 μg/L,
because patients were clinically unstable. Overall, the
rate of PCT-guided algorithm was 53 % [42].
Finally, in the PASS trial [47], 56 of 312 (17.9 %)
patients with baseline “alert PCT" did not receive anti-
microbials. Unfortunately, none of the studies assessed
specifically the outcomes of the patients with algorithm
overruling.Length of ICU stay and organ failure
All studies provided data concerning the LOS (in days)
in the ICU that was very similar in the PCT and control
groups: 16.1 ± 6.9 vs. 19.4 ± 8.9 [43], 4 (1–21) vs. 7 (1–
91) [41], 16.4 ± 8.3 vs. 16.7 ± 5.6 [44], 13 (7–21) vs. 13.5
(8–22.2) [45], 15.5 ± 12.5 vs. 17.7 ± 10.1 [46], 15.9 ±
16.1 vs. 14.4 ± 14.1 [42], and 6 [3-12] vs. 5 [3-11] [47].
An objective assessment of organ failures is provided
in only two trials [42,47]. Baseline organ failures were
similar in both groups. However, in the PRORATA trial,
the SOFA score was higher in the PCT group at day 28
(p = 0.037) [42]. In the PASS study, the number of days
on mechanical ventilation was significantly higher in the
PCT-guided group: 3,569 days (65.5 %) vs. 2,861 days
(60.7 %; p < 0 .001) [47].Rates of superinfections and relapses
Three studies provide the rate of superinfections. One
was lower in PCT-guided arm: 7/31 (22.5 %) vs. 11/37
(29.7 %) [41]. The other two were higher in the PCT
group: 7/51 (13.7 %) vs. 6/50 (12 %) [45] and 106/307
(34.5 %) vs. 97/314 (30.9 %) [42].
Two studies provided data on the rates of infection re-
lapse that were similar in one study: 1/39 (2.6 %) vs. 1/
40 (2.5 %) [41]; the second was slightly higher in the
PCT arm: 20/307 (6.5 %) vs. 16/314 (5.1 %) [45].
Finally, two studies monitored the emergence of multi-
drug resistance bacteria with very different overall rates.
In the PRORATA study [42], the rate of multidrug re-
sistance bacteria in the PCT arm was 17.9 % vs. 16.6 %
(p = 0.67), whereas the PASS was significantly higher in
the control group: 2.4 % vs. 3.1 % (p = 0.01) [47].
Mortality
All studies provided 28-day all-cause mortality rates
that were comparable. A closer look showed that in
four trials, the 28-day mortality was very similar:
8/39) (20.5 %) vs. 8/40 (20 %) [41]; 3/14 (21.4 %) vs.
3/13 (23.1 %) [44]; 15/57 (26.3 %) vs. 14/53 (26.4 %)
[46]; 65/307 (21.2 %) vs. 64/314 (20.4 %) (p = NS)
[42]; and 190/604 (31.5 %) vs. 191/596 (32 %) [47]. In
two trials, the mortality in the control group was
higher, although not significantly: 10/38 (26 %) vs. 13/
34 (38 %) (p = 0.28) [43] and 8/51 (16 %) vs. 12/50
(24 %) (p = 0.327) [45].
In the two larger studies, the PRORATA [42] and the
PASS [47], the 60-day mortality also was provided. In
the PRORATA, the 60-day mortality was 3.8 % higher in
the PCT-guided group, which represents a 10 % increase
in the relative risk of death. However, both the design
and the power cannot exclude a negative impact on
mortality attributable to the PCT strategy [50]. In the
PASS study, the 60-day mortality was similar: 38.2 % vs.
36.9 %.
Associated costs
It is well known that a prolonged duration of antibiotic
therapy is associated with increased costs. Conversely,
the measurement of PCT also is very expensive. The
analysis of the cost-benefit of the implementation of
a PCT algorithm was not performed in any of the
selected studies.
Conclusions
Biomarkers of infection, namely CRP and PCT, are po-
tentially very useful in the diagnosis of infection as well
as in the assessment of its response to antibiotic therapy.
Presently, no RCTs of CRP-guided therapy in critically
ill patients have been performed. Regarding PCT, in sev-
eral RCTs, PCT guidance was repeatedly associated with
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ever, these trials present several limitations, namely high
rate of patients’ exclusion, high rate of algorithm over-
ruling, long duration of antibiotic therapy in the control
group, disregard the effect of renal failure or use of RRT
on PCT levels, and above all a possible higher mortality
and late organ failure in the PCT arm. In addition, some
infections as well as frequent nosocomial bacteria were
not evaluated. As a result, in critically ill patients, we
cannot recommend the routine use of PCT-guided algo-
rithms of antibiotic stewardship to assist the clinical
decision-making process at the bedside. However, bio-
markers, namely PCT and CRP but also platelet count,
d-dimer, and prothrombin time, could be very useful at
the bedside but should never be used solely. Biomarkers
should always be used in conjunction with a complete
clinical, laboratory, and radiologic evaluation and with a
perfect knowledge of its biology, strengths, and limita-
tions. Future studies in this area of knowledge are
needed, but their design should take into account the
issues identified in the present review to define clearly
the role of biomarkers at the beside.
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